• Menu

  • Nexalin Technology

    • The Nexalin Technology

    Nexalin® Technology is a patented breakthrough of Dr. Katsnelson’s life’s work. The continued advancement in the Nexalin-related technologies is one of the goals of Kalaco Scientific, Inc. This advancement will include various therapies for different indications as well as making technological advances. Kalaco will seek to patent the technological advances.

    Kalaco’s regulatory approvals include: FDA clearance for the use of the Nexalin Technology for Anxiety, Depression, and Insomnia; no other indications are currently authorized in the United States.

    European Union

    In the European Union, the Nexalin Technology is approved for relief of musculoskeletal pain as well as anxiety, depression, and insomnia.
    Switzerland

    In Switzerland, Kalaco has received the approval and acceptance of the CE Marking for relief of musculoskeletal pain and the treatment of anxiety, depression, and insomnia.
    Russia

    In Russia, Kalaco has approval of the Nexalin Devices for use in medical practice.
    United States

    Kalaco has been issued patents on this Nexalin Technology in the United States, Australia, Russia, Canada, South Africa, and Taiwan.
    Australia

    In Australia, Kalaco has received approval from the Therapeutic Goods Administration (TGA) - The equivalent of the United States FDA - for the relief of musculoskeletal pain, as well as the treatment of anxiety, depression, and insomnia. Kalaco has received the official trademark certificate for "Nexalin."

    Kalaco currently has clearance in the United States for Anxiety, Depression, and Insomnia. Other intended uses are approved in other countries, but not yet in the United States and require investigation and FDA market authorization before the Nexalin™ technology can be offered for those uses.


    All contents © copyright 2009 Kalaco Scientific, Inc. All Rights reserved.